AURORA, ON, Dec. 8 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") announced today that its Annual General Meeting of shareholders previously scheduled to take place on Thursday, January 4, 2007, will now be held on Tuesday, January 23, 2007 at 10:00am. The meeting will take place at the Sheraton Parkway Toronto North, 600 Highway 7 East, Richmond Hill, Ontario, L4B 1B2. The meeting will also be both an Annual and a Special Meeting.
WHAT: ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF
HELIX BIOPHARMA CORP.
WHERE: Sheraton Parkway Toronto North, 600 Highway 7 East,
Richmond Hill, Ontario, L4B 1B2
WHEN: TUESDAY, JANUARY 23, 10:00am. (EST)
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".
The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. The time, place and date of the Annual and Special Meeting are subject to change on limited notice. This News Release contains certain forward-looking statements regarding the Company's Annual and Special Meeting and the Company's research and development initiatives, which statements can be identified by the use of forward-looking terminology such as "developing", "initiatives" or that events "will" occur, or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research & development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; uncertainty as to whether the Company's products will be successfully commercialized, or at all; Helix's need for additional future capital, which may not be available in a timely manner or at all; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in the Company's Annual Information Form and other filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, opinions or expectations, or other circumstances change.